BRPI0417241A - agente e processo para a prevenção e/ou para o tratamento de disfunção do cérebro superior, e, uso de um derivado de xantina, ou um sal farmaceuticamente aceitável do mesmo - Google Patents
agente e processo para a prevenção e/ou para o tratamento de disfunção do cérebro superior, e, uso de um derivado de xantina, ou um sal farmaceuticamente aceitável do mesmoInfo
- Publication number
- BRPI0417241A BRPI0417241A BRPI0417241-8A BRPI0417241A BRPI0417241A BR PI0417241 A BRPI0417241 A BR PI0417241A BR PI0417241 A BRPI0417241 A BR PI0417241A BR PI0417241 A BRPI0417241 A BR PI0417241A
- Authority
- BR
- Brazil
- Prior art keywords
- acceptable salt
- agent
- xanthine derivative
- prevention
- brain dysfunction
- Prior art date
Links
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title abstract 3
- 230000005978 brain dysfunction Effects 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"AGENTE E PROCESSO PARA A PREVENçãO E/OU PARA O TRATAMENTO DE DISFUNçãO DO CéREBRO SUPERIOR, E, USO DE UM DERIVADO DE XANTINA, OU UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO". Um agente preventivo e/ou terapêutico para disfunções do cérebro superior que contém, como um ingrediente ativo, um derivado de xantina representado, por exemplo, pela fórmula (I) a seguir ou por um sal farmacologicamente aceitável da mesma: (I) (II) em que R¬ 1¬, R¬ 2¬ e R¬ 3¬ são os mesmos ou diferentes e cada um representa hidrogênio, alquila inferior, alquenila inferior ou alquinila inferior; R¬ 4¬ representa cicloalquila, -(CH~ 2~)~ n~-R¬ 5¬ ou a fórmula (II) fornecida a seguir e X¬ 1¬ e X¬ 2¬ são os mesmos ou diferentes e cada um representa oxigênio ou enxofre.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003410432 | 2003-12-09 | ||
| PCT/JP2004/018765 WO2005056016A1 (ja) | 2003-12-09 | 2004-12-09 | 高次脳機能障害の予防および／または治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0417241A true BRPI0417241A (pt) | 2007-03-06 |
Family
ID=34674933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0417241-8A BRPI0417241A (pt) | 2003-12-09 | 2004-12-09 | agente e processo para a prevenção e/ou para o tratamento de disfunção do cérebro superior, e, uso de um derivado de xantina, ou um sal farmaceuticamente aceitável do mesmo |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20070078148A1 (pt) |
| EP (1) | EP1709966A4 (pt) |
| JP (1) | JPWO2005056016A1 (pt) |
| KR (1) | KR20060124615A (pt) |
| CN (1) | CN1889959A (pt) |
| AU (1) | AU2004296137A1 (pt) |
| BR (1) | BRPI0417241A (pt) |
| CA (1) | CA2550130A1 (pt) |
| WO (1) | WO2005056016A1 (pt) |
| ZA (1) | ZA200604723B (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9101580B2 (en) | 2012-12-18 | 2015-08-11 | Matthew Bennett | Compositions and methods for treating traumatic brain injury |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4755517A (en) * | 1986-07-31 | 1988-07-05 | Warner-Lambert Company | Derivatives of xanthine, pharmaceutical compositions and methods of use therefor |
| GB8906792D0 (en) * | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
| FR2665636B1 (fr) * | 1990-08-10 | 1994-10-07 | Adir | Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer. |
| JPH08512281A (ja) * | 1993-02-26 | 1996-12-24 | メレル ダウ ファーマス−ティカルズ インコーポレイテッド | アデノシンａ▲下１▼受容体拮抗剤としてのキサンチン誘導体類 |
| CA2161011A1 (en) * | 1994-02-23 | 1995-08-31 | Fumio Suzuki | Xanthine derivatives |
| EP1666041A3 (en) * | 1997-09-05 | 2008-04-02 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives for treating neurodegenerative disorders |
| CA2446828C (en) * | 2001-05-08 | 2011-01-04 | Blanchette Rockefeller Neurosciences Institute | Adenosine a1 receptor antagonists for treating hypoxia-induced learning and memory impairment |
| AR056615A1 (es) * | 2002-12-27 | 2007-10-17 | Kyowa Hakko Kogyo Kk | Un metodo de tratamiento de trastornos de la conducta |
-
2004
- 2004-12-09 BR BRPI0417241-8A patent/BRPI0417241A/pt not_active IP Right Cessation
- 2004-12-09 CN CNA2004800362670A patent/CN1889959A/zh active Pending
- 2004-12-09 AU AU2004296137A patent/AU2004296137A1/en not_active Abandoned
- 2004-12-09 KR KR1020067011123A patent/KR20060124615A/ko not_active Withdrawn
- 2004-12-09 US US10/579,829 patent/US20070078148A1/en not_active Abandoned
- 2004-12-09 JP JP2005516245A patent/JPWO2005056016A1/ja active Pending
- 2004-12-09 CA CA002550130A patent/CA2550130A1/en not_active Abandoned
- 2004-12-09 WO PCT/JP2004/018765 patent/WO2005056016A1/ja not_active Ceased
- 2004-12-09 EP EP04807124A patent/EP1709966A4/en not_active Withdrawn
-
2006
- 2006-06-08 ZA ZA200604723A patent/ZA200604723B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1709966A4 (en) | 2009-04-29 |
| JPWO2005056016A1 (ja) | 2007-07-05 |
| EP1709966A1 (en) | 2006-10-11 |
| CA2550130A1 (en) | 2005-06-23 |
| AU2004296137A1 (en) | 2005-06-23 |
| CN1889959A (zh) | 2007-01-03 |
| ZA200604723B (en) | 2009-11-25 |
| US20070078148A1 (en) | 2007-04-05 |
| KR20060124615A (ko) | 2006-12-05 |
| WO2005056016A1 (ja) | 2005-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0418082A (pt) | antagonista de receptor de adenosina a2a, agente para tratar e/ou prevenir doenças, composto, composição farmacêutica, e, método para tratar e/ou prevenir doenças associadas com receptor de adenosina a2a | |
| BR0015624A (pt) | Uso de um composto, composto, composição farmacêutica, e, método de tratamento ou profilaxia de doenças ou condições humanas | |
| AU2003301020A8 (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
| MXPA04007470A (es) | Piridinonas sustituidas. | |
| BRPI0314308B8 (pt) | antagonistas de opióide, seus usos, e composição farmacêutica | |
| BRPI0708038B8 (pt) | derivado de cumarina, composição farmacêutica e agente terapêutico para um distúrbio proliferativo celular | |
| BRPI0407283A (pt) | Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade | |
| TW200517109A (en) | Substituted pyridinones | |
| ECSP045139A (es) | DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTICA DE MGluR5 | |
| NO20021328L (no) | Pyrazolopyrimidier som terapeutiske midler | |
| BRPI0517423A (pt) | composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto | |
| BR0311806A (pt) | Derivados heteroaril benzocondensado-amida de tienopiridinas úteis como agentes terapêuticos, composições farmacêuticas que os incluem e métodos para o seu uso | |
| NO990433L (no) | Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet | |
| BR0213464A (pt) | Derivados de 3-azabiciclo[3.1.0]hexano como antagonistas receptores de opióide | |
| MXPA04005209A (es) | Antagonistas del receptor de adenosina a2a. | |
| UA85541C2 (ru) | Карбаматные производные хинуклидина и фармацевтическая композиции, которая содержит эти соединения | |
| EP1201239A4 (en) | CCR3 CYCLIC AMINE ANTAGONISTS | |
| UA85708C2 (ru) | Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей | |
| EA200400466A1 (ru) | Производные пиперазина с антагонистической активностью к рецептору ccr1 | |
| MXPA04005156A (es) | Antagonistas del receptor de adenosina a2a. | |
| DE60100994D1 (de) | Transdermales therapeutisches System für die Erzielung hoher Plasmaspiegel von Rotigotin in der Therapie von Morbus Parkinson | |
| BR0315777A (pt) | Uso de derivados de piperazina como antagonistas ccr1 | |
| BRPI0414011A (pt) | naftalencarboxamidas e seus derivados úteis como novos agentes antiangiogênicos | |
| YU75603A (sh) | Dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja | |
| BR0210238A (pt) | Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |